A Phase 2 Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma In Situ of the Bladder.

Roger Li Wade J Sexton Jasreman Dhillon Anders E Berglund Shreyas Naidu Gustavo J Borjas Kyle M Rose Youngchul Kim Xuefeng Wang José R Conejo-Garcia Rohit K Jain Michael A Poch Philippe E Spiess Julio M Pow-Sang Scott M Gilbert Jingsong Zhang

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Durvalumab monotherapy conferred minimal efficacy in treating BCG-unresponsive CIS of the bladder, with 6mo complete response of 12%. Complement activation is a potential mechanism behind treatment resistance.

Keyphrases

urinary tract
spinal cord injury
open label
combination therapy
high grade
clinical trial
randomized controlled trial
human health
risk assessment
muscle invasive bladder cancer